Use of clazakizumab for amelioration of desensitization and kidney transplantation in HLA-sensitized patients

摘要

A method for desensitization of a patient in need of an organ transplant is provided. Human leukocyte antigen-sensitized patients awaiting incompatible kidney transplantation were treated with clazakizumab, resulting in reduced or eliminated levels of donor-specific antibodies and improved transplantation rates. Clazakizumab and variants are provided for use in various embodiments of the methods. In some embodiments, clazakizumab or a variant thereof is administered concurrently or sequentially with the intravenous immunoglobulin.